Prostatic intraepithelial neoplasia: Its morphological and molecular diagnosis and clinical significance - Abstract

Institute of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy.

Unit of Anatomic Pathology, Cordoba University Medical School, Cordoba, Spain; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.



What's known on the subject? and What does the study add? HGPIN is the precursor lesion to some forms of adenocarcinoma. HGPIN should not be confused with intraductal carcinoma. The latter, even when isolated in a prostate biopsy, carries a predictive value of 100% for cancer in a repeat biopsy. Multifocal HGPIN, when isolated in a prostate biopsy, still carries a high predictive value for carcinoma in repeat biopsy. Adenosis and PIA are not considered as precursor lesions. The aim of the present paper was to review the morphological spectrum of prostatic intraepithelial neoplasia (PIN), its relationship to carcinoma of the prostate (PCa) and its clinical significance. We reviewed the literature on premalignant lesions of the prostate, with an emphasis on high grade prostatic intraepithelial neoplasia (HGPIN). HGPIN is the most likely precursor of PCa, according to almost all available evidence. HGPIN is characterized by cellular proliferations within pre-existing ducts and acini, with nuclear and nucleolar enlargement similar to PCa. The clinical importance of recognizing HGPIN is based on its association with PCa. In recent years, a significant decline from 36% to 22% in the predictive value of cancer after an initial diagnosis of HGPIN. A major factor contributing to the decreased incidence of cancer after a diagnosis of HGPIN on needle biopsy in the contemporary era is related to increased needle biopsy core sampling, which detects many associated cancers on initial biopsy. Some recent studies have suggested that molecular findings associated with HGPIN might be able to predict which men are more likely to have cancer on re-biopsy.

Written by:
Montironi R, Mazzucchelli R, Lopez-Beltran A, Scarpelli M, Cheng L.   Are you the author?

Reference: BJU Int. 2011 Aug 26. Epub ahead of print.
doi: 10.1111/j.1464-410X.2011.010413.x

PubMed Abstract
PMID: 21883826 Prostate Cancer Section